Acceleron Pharma Company Profile (NASDAQ:XLRN)

Analyst Ratings

Consensus Ratings for Acceleron Pharma (NASDAQ:XLRN) (?)
Ratings Breakdown: 8 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $50.33 (48.39% upside)

Analysts' Ratings History for Acceleron Pharma (NASDAQ:XLRN)
Show:
DateFirmActionRatingPrice TargetActions
7/10/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Morgan StanleyReiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Barclays PLCBoost Price TargetOverweight$40.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016FBR & CoReiterated RatingBuy$63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Janney Montgomery ScottUpgradeNeutral -> Buy$45.00 -> $39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015JMP SecuritiesBoost Price TargetMarket Outperform$52.00 -> $58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015Citigroup Inc.Boost Price TargetBuy$50.00 -> $52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Acceleron Pharma (NASDAQ:XLRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016Q216($0.50)$3.77 millionN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2016Q116($0.26)$0.14$8.70 million$18.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.09)($0.81)$15.70 million$3.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.46)($0.36)$4.38 million$4.16 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.49)($0.32)$4.23 million$5.72 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.43)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015Q414($0.23)($0.55)$3.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014($0.27)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.55)($0.54)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2014Q114($0.44)($0.30)$2.85 million$3.31 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2014Q413($0.08)($0.64)$13.66 million$11.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013($0.19)($5.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Acceleron Pharma (NASDAQ:XLRN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.43)($0.10)($0.27)
Q2 20163($0.59)($0.45)($0.52)
Q3 20162($0.63)($0.54)($0.59)
Q4 20162($0.69)($0.59)($0.64)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Acceleron Pharma (NASDAQ:XLRN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Acceleron Pharma (NASDAQ:XLRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/6/2016John L KnopfCEOSell100,000$33.87$3,387,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2016John L KnopfCEOSell30,501$33.26$1,014,463.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2016Steven D ErtelCOOSell32,270$34.56$1,115,251.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016John L KnopfCEOSell28,022$34.72$972,923.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Kevin F MclaughlinCFOSell25,300$34.66$876,898.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Matthew L ShermanEVPSell26,000$34.74$903,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2016Steven D ErtelCOOSell28,304$34.77$984,130.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016John L KnopfCEOSell100,000$33.07$3,307,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2016Matthew L ShermanEVPSell26,000$32.00$832,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2016Steven D ErtelCOOSell32,270$32.00$1,032,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Corp /De/ CelgeneMajor ShareholderBuy800,000$40.00$32,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Matthew L. ShermanEVPSell6,000$23.28$139,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015John L. KnopfCEOSell19,000$24.38$463,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Kevin F. MclaughlinCFOSell7,000$24.38$170,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2015Matthew L. ShermanEVPSell2,000$33.24$66,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Ravindra KumarVPSell33,000$35.00$1,155,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Steven D. ErtelCOOSell2,000$33.61$67,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015John D. QuiselSVPSell5,500$33.35$183,425.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015John L. KnopfCEOSell19,000$30.20$573,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Kevin F. MclaughlinCFOSell6,500$30.16$196,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Matthew L ShermanEVPSell7,000$31.13$217,910.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015John D QuiselSVPSell5,500$30.83$169,565.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Matthew L ShermanEVPSell6,000$32.46$194,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Steven D ErtelCOOSell2,000$31.38$62,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015John D QuiselSVPSell5,500$30.00$165,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2015John L KnopfCEOSell19,000$29.70$564,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2015Kevin F MclaughlinCFOSell7,000$29.70$207,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Matthew L ShermanEVPSell7,000$31.54$220,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015John D QuiselSVPSell5,500$31.13$171,215.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Steven D ErtelCOOSell2,000$31.11$62,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015John L KnopfCEOSell19,000$32.51$617,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Kevin F MclaughlinCFOSell6,500$32.49$211,185.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Matthew L ShermanEVPSell7,000$32.37$226,590.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Steven D ErtelCOOSell2,000$31.49$62,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Matthew L ShermanEVPSell5,000$33.52$167,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Steven D ErtelCOOSell2,000$33.58$67,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2015John L KnopfCEOSell20,000$34.87$697,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2015Kevin F MclaughlinCFOSell7,000$34.88$244,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2015Matthew L ShermanEVPSell6,000$41.18$247,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015John D QuiselSVPSell9,500$41.00$389,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015John L KnopfCEOSell20,000$40.25$805,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Kevin F MclaughlinCFOSell6,500$40.25$261,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Matthew L ShermanSVPSell7,000$41.64$291,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Steven D ErtelSVPSell2,000$40.58$81,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Kevin F MclaughlinCFOSell2,000$40.66$81,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Ravindra KumarVPSell1,500$40.80$61,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015John L KnopfCEOSell20,000$39.62$792,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015Kevin F MclaughlinCFOSell5,000$39.46$197,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Ravindra KumarVPSell4,000$38.46$153,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Steven D ErtelSVPSell5,000$38.47$192,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Edwin M Kania JrDirectorSell54,350$38.00$2,065,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Matthew L ShermanSVPSell5,000$40.16$200,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014John D QuiselSVPSell4,000$41.35$165,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Jean GeorgeDirectorSell97,407$44.90$4,373,574.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014John L KnopfCEOSell20,000$43.99$879,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Kevin F MclaughlinCFOSell10,000$44.02$440,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Tom ManiatisDirectorSell23,400$45.00$1,053,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Ravindra KumarVPSell4,000$35.88$143,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Steven D ErtelSVPSell7,500$35.87$269,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Matthew L ShermanSVPSell5,082$33.76$171,568.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Ravindra KumarVPSell16,000$34.53$552,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2014Tom ManiatisDirectorSell23,400$35.00$819,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014John L KnopfCEOSell20,000$29.71$594,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Matthew L ShermanSVPSell5,082$29.50$149,919.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Kevin F MclaughlinCFOSell10,000$29.25$292,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Ravindra KumarVPSell11,000$29.89$328,790.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Steven D ErtelSVPSell10,000$29.66$296,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014John D QuiselSVPSell7,000$30.01$210,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Matthew L ShermanSVPSell5,000$25.48$127,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014John D QuiselSVPSell2,000$25.43$50,860.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014John L KnopfCEOSell20,000$24.46$489,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Kevin F MclaughlinCFOSell10,000$24.48$244,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014John L KnopfCEOSell6,700$24.92$166,964.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Kevin F MclaughlinCFOSell3,300$24.90$82,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2014Matthew L ShermanSVPSell5,000$25.82$129,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Matthew L ShermanSVPSell2,500$29.62$74,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014John D QuiselSVPSell13,000$29.98$389,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014John L KnopfCEOSell17,500$29.78$521,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Kevin F MclaughlinCFOSell10,000$29.78$297,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Ravindra KumarVPSell9,000$29.97$269,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2014Matthew L ShermanSVPSell2,500$26.22$65,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014John D QuiselSVPSell5,000$29.73$148,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2014Matthew L ShermanSVPSell7,500$28.99$217,425.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014John L KnopfCEOSell17,500$31.74$555,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Kevin F MclaughlinCFOSell10,000$31.72$317,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Ravindra KumarVPSell2,000$34.10$68,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Steven D ErtelSVPSell10,000$34.09$340,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2014Jean GeorgeDirectorSell10,491$35.01$367,289.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2014Jean GeorgeDirectorSell25,477$35.16$895,771.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2014Ravindra KumarVPSell7,000$35.00$245,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Matthew L ShermanSVPSell2,500$34.42$86,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014John D QuiselVPSell9,000$33.94$305,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2014Matthew L ShermanSVPSell7,500$33.23$249,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014John L KnopfCEOSell15,000$31.65$474,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Kevin F MclaughlinCFOSell10,000$31.65$316,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014John KnopfCEOSell15,000$31.52$472,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014John QuiselVPSell9,000$31.43$282,870.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Steven ErtelSVPSell10,000$31.52$315,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Corp /De/ Celgenemajor shareholderBuy1,100,000$42.86$47,146,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Jean GeorgeDirectorSell215,644$42.86$9,242,501.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2014Edwin Kania, Jr.DirectorSell1,000,000$32.05$32,050,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2014Ravindra KumarVPSell2,000$35.86$71,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2014Steven ErtelSVPSell2,500$35.87$89,675.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2014Corp /De/ CelgeneMajor ShareholderBuy300,000$50.00$15,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2013Corp /De/ CelgeneMajor ShareholderBuy666,667$15.00$10,000,005.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Acceleron Pharma (NASDAQ:XLRN)
DateHeadline
07/29/16 07:29 AMAcceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : July 29, 2016 -
07/28/16 06:00 AMAcceleron Pharma to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016 - [Business Wire] - Acceleron Pharma Inc. , a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that the Company will host a live conference call and webcast on Thursday, August 4, 2016 at 8:00 a.m.
07/27/16 07:51 PMAcceleron Pharma Inc. (XLRN) Jumps 5.45% on July 27 - Equities.com
07/25/16 03:28 PMAcceleron Pharma Appoints Thomas McCourt to its Board of Directors - [at noodls] - July 25, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates ...
07/25/16 03:17 PMACCELERON PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers -
07/22/16 07:09 PMAcceleron Pharma Inc. (NASDAQ:XLRN): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 07:43 PMEquity Roundup: Stock Performance Focus on Acceleron Pharma Inc. (NASDAQ:XLRN) - Press Telegraph
07/19/16 08:18 AMAcceleron Pharma Incorporated (NASDAQ:XLRN) Short Interest Decreased By 4.22% - Consumer Eagle
07/18/16 04:49 AMShare Performance Summary for: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Press Telegraph
07/16/16 10:32 AMShares Experiencing a Downtrend: Acceleron Pharma, Inc. (NASDAQ:XLRN) - TGP
07/15/16 06:23 PMAcceleron Pharma Inc. (NASDAQ:XLRN) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 06:23 PMAnalyst Target and Average Rating Watch: Acceleron Pharma Inc. (NASDAQ:XLRN) - Press Telegraph
07/15/16 06:23 PMBroker Outlook For Acceleron Pharma Inc. (XLRN) - Fiscal Standard
07/14/16 07:37 PMWhat's in Acceleron Pharma Inc After Today's Huge Decline? - Consumer Eagle
07/14/16 07:37 PMAcceleron Pharma Inc Realized Volatility Hits Extreme Level - CML News
07/14/16 07:37 PMAcceleron Pharma Inc. (XLRN) Drops 6.35% on July 13 - Equities.com
07/12/16 07:36 PMOption Market: Acceleron Pharma Inc Risk Hits An Elevated Level - CML News
07/12/16 07:36 PMHow Analysts Feel About Acceleron Pharma Inc (NASDAQ:XLRN)? - Press Telegraph
07/11/16 04:31 AMStock on the Rise for the Quarter: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Engelwood Daily
07/11/16 04:31 AMStock Rating Watch and Earnings Insight for Acceleron Pharma Inc. (NASDAQ:XLRN) - Press Telegraph
07/11/16 04:31 AMStock Performance Rundown on: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Press Telegraph
07/09/16 06:30 PMShares Finishing Down for the Week Acceleron Pharma, Inc. (NASDAQ:XLRN) - Engelwood Daily
07/08/16 07:17 PMCan Acceleron Pharma Inc. (NASDAQ:XLRN) Improve on the Earnings Front? - Engelwood Daily
07/08/16 07:17 PMWill Acceleron Pharma Inc. (NASDAQ:XLRN) Surprise Analysts? - Investor Newswire
07/08/16 07:17 PMAcceleron Pharma (XLRN) ACE-083 Phase 1 Shows Statistically-Significant Results - StreetInsider.com
07/08/16 10:10 AMCompany Stock Focus for Acceleron Pharma Inc. (NASDAQ:XLRN): Which Way Will Shares Head? - Press Telegraph
07/08/16 06:21 AMAcceleron Announces ACE-083 Phase 1 Results at the 14th International Congress on Neuromuscular Diseases - [at noodls] - July 8, 2016 -ACE-083 increased muscle volume of the tibialis anterior muscle by 8.9% in healthy volunteers- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical ...
07/07/16 10:02 AMCEO and President of Acceleron Pharma Inc (NASDAQ:XLRN), Knopf John L, sells 28,022 shares worth $973,055
07/06/16 04:57 AMShares Dropping Lower in Session: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Telanagana Press
07/06/16 04:57 AMShare Volatility in Focus: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Engelwood Daily
07/05/16 04:40 AMAcceleron Pharma Inc. (XLRN) Broker Price Targets For The Coming Week - Fiscal Standard
07/03/16 06:29 PMShare Performance Recap for: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Press Telegraph
07/03/16 04:37 AMAcceleron Pharma Incorporated (NASDAQ:XLRN) Shorted Shares Decreased By 4.22% - Press Telegraph
06/30/16 07:35 PMAcceleron Pharma Inc. (XLRN) Jumps 6.44% on June 28 - Equities.com
06/29/16 10:01 AMAcceleron Pharma Inc. (NASDAQ:XLRN) Company Rating and Target Watch - Telanagana Press
06/29/16 10:01 AMWere Analysts Bearish Acceleron Pharma Inc (NASDAQ:XLRN) This Week? - Press Telegraph
06/29/16 10:01 AMAcceleron Pharma Incorporated (NASDAQ:XLRN) Sellers Covered 4.22% of Their Shorts - Press Telegraph
06/29/16 06:21 AMAcceleron Announces Presentation of ACE-083 Phase 1 Healthy Volunteer Data at the 14th International Congress on Neuromuscular Disease - [at noodls] - June 29, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates ...
06/28/16 08:58 AMAcceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : June 28, 2016 -
06/27/16 04:28 AMStock Performance Focus on: Acceleron Pharma, Inc. (NASDAQ:XLRN) - Press Telegraph
06/27/16 04:28 AMShare Update and Earnings Review for Acceleron Pharma Inc. (NASDAQ:XLRN) - Press Telegraph
06/27/16 04:28 AMNext Weeks Broker Price Targets For Acceleron Pharma Inc. (XLRN) - Fiscal Standard
06/25/16 10:58 AMStock Tracing Lower on the Week Acceleron Pharma, Inc. (NASDAQ:XLRN) - Engelwood Daily
06/25/16 10:58 AMCan Acceleron Pharma Inc. (NASDAQ:XLRN) Keep Up with Analyst Expectations? - Investor Newswire
06/24/16 09:58 AMAnalysts Confident In Acceleron Pharma's Drug Trial Outcomes - Benzinga
06/24/16 09:58 AMCovering the Bases on Acceleron Pharma Inc. (NASDAQ:XLRN): Where is the Stock Going? - Press Telegraph
06/23/16 08:10 PMAnalysts Confident In Acceleron Pharma's Drug Trial Outcomes
06/23/16 09:53 AMAcceleron Pharma, Inc. (NasdaqGM:XLRN) Stock Momentum Hits Strength - CML News
06/21/16 04:43 AMBarclays Maintains Acceleron Pharma Inc to Overweight with Price Target $42.00 - TheFounders Daily
06/21/16 04:43 AMAcceleron Pharma (XLRN) Is Today's Dead Cat Bounce Stock - TheStreet.com

Social

About Acceleron Pharma

Acceleron Pharma logoAcceleron Pharma Inc. is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia. Its Sotatercept is an investigational protein therapeutic that manages red blood cell levels by targeting molecules in the transforming growth factor beta (TGF-β) superfamily, which is being evaluated in Phase IIa studies. Its Dalantercept is an investigational protein therapeutic that inhibits angiogenesis by preventing bone morphogenetic proteins 9 (BMP) and BMP10, proteins in the TGF-β superfamily, which is being evaluated in Phase II studies. Its ACE-083 is an investigational protein therapeutic that helps to manage muscle mass and strength in specific muscles and muscle groups, which is being evaluated in Phase I studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: XLRN
  • CUSIP:
Key Metrics:
  • Previous Close: $33.92
  • 50 Day Moving Average: $34.03
  • 200 Day Moving Average: $30.92
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.26B
  • Beta: 1.66
  • Current Year EPS Consensus Estimate: $-1.55 EPS
  • Next Year EPS Consensus Estimate: $-1.74 EPS
Additional Links:
Acceleron Pharma (NASDAQ:XLRN) Chart for Friday, July, 29, 2016